Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with aromatase inhibitor in advanced HER2-negative, hormone receptor-positive breast cancer
ChiCTR1800018923Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in breast cancer, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Progression-free survival. Started Oct 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1800018923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018923.